Jenburkt Pharmaceuticals Limited reported an 8.34% year-on-year increase in net profit after tax (PAT) to ₹3,473.60 lacs for the financial year ended March 31, 2026, driven by robust top-line growth and operational efficiencies. Revenue from operations rose 13.02% to ₹16,874.06 lacs, reflecting strong demand across its pharmaceutical portfolio. The Board of Directors recommended a final dividend of ₹20.70 per equity share, representing a 207% payout on the ₹10 face value, signaling confidence in the company’s cash generation capabilities.

The results were filed with the Bombay Stock Exchange under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The 41st Annual General Meeting (AGM) is scheduled for September 4, 2026, where shareholders will vote on the adoption of financial statements audited by M/s. D. R. Mehta & Associates. A key agenda item involves the reappointment of Dilip H. Bhuta as Whole Time Director and Chief Financial Officer for five years, alongside ratifying the remuneration of cost auditor M/s. Kirit Mehta & Co. LLP at ₹2,75,000 plus taxes for FY27.

Financial Performance Overview

The company’s total income reached ₹17,904.00 lacs, up from ₹15,841.25 lacs in FY25. Profit before tax increased 14.88% to ₹4,651.89 lacs, although this figure includes exceptional items related to revised labor codes. Earnings per share (EPS) grew to ₹78.71 from ₹72.65 in the previous year. Reserves and surplus expanded by 15.09% to ₹19,262.69 lacs, reinforcing the balance sheet strength.

What the Numbers Show

A significant divergence exists between pre-tax profit growth and net profit growth due to exceptional items. The company recorded ₹395.11 lacs in exceptional expenses arising from past service costs linked to the implementation of new labor codes notified in November 2025. Without this one-time charge, underlying profitability would have been substantially higher. Additionally, other income surged to ₹1,029.94 lacs from ₹672.10 lacs, contributing materially to total income through interest earnings and foreign exchange gains.

Governance and Corporate Actions

Shareholders will decide on the reappointment of Dilip H. Bhuta, who has served since July 2013. His proposed remuneration is capped at ₹108.00 lacs per annum for three years starting April 2027. The company also highlighted its CSR initiatives, spending ₹65.00 lacs on healthcare projects, including the 'Asha Van' for cancer screening in rural Gujarat. Statutory auditors D. R. Mehta & Associates issued an unmodified opinion, while secretarial auditor Nilesh Shah & Associates confirmed compliance with corporate governance norms.

jenburkt pharmaceuticals has closed its trading window for all designated persons, insiders, and connected persons, including their relatives, effective July 1, 2026. This measure is in accordance with the company’s Code on Prohibition of Insider Trading and the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The restriction is implemented to prevent potential insider trading ahead of the release of price-sensitive information.

The trading window will remain closed until 48 hours after the company disseminates the standalone unaudited financial results for the quarter ending June 30, 2026. This closure ensures that no insider trades occur while the market is unaware of the quarterly performance data. The company stated that the specific schedule for the board meeting, which will consider these unaudited financial results, will be communicated to the exchange separately at a later date.

The closure applies to all trades in the equity shares of Jenburkt Pharmaceuticals Limited by the specified individuals. The notification was signed by Ashish Rasiklal Shah, Senior Vice President, Company Secretary, and Compliance Officer. The company has requested the stock exchange to take the closure of the trading window on record.